Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 1—January 2007

Blood Transfusion and Spread of Variant Creutzfeldt-Jakob Disease

Klaus Dietz*Comments to Author , Günter Raddatz*, Jonathan Wallis†, Norbert Müller‡, Inga Zerr§, Hans-Peter Duerr*, Hans Lefèvre¶, Erhard Seifried#, and Johannes Löwer**
Author affiliations: *University of Tübingen, Tübingen, Germany; †Freeman Hospital, Newcastle upon Tyne, United Kingdom; ‡University Hospital Essen, Essen, Germany; §University of Göttingen, Göttingen, Germany; ¶DRK Blood Donor Service West, Hagen, Germany; #DRK Blood Donor Service Baden-Württemberg, Hessen, Frankfurt am Main, Germany; **Paul-Ehrlich-Institute, Langen, Germany;

Main Article

Table 1

Summary of input parameters for the model*

Age-specific mortality ratesU-shaped, with minimum at age 10.Federal Statistical Office of Germany
Donor recruitmentDonors ages 18–67 y. Maximum recruitment rate at age 18, lower plateau ages 25–50; further decrease until age 67.Age-distribution of first-time donors at DRK Blood Service and age structure in population
Proportion of donors3% of population.DRK Blood Service West
Duration as active donorDonors ages 18–40 y, mean duration as active donor 10–14 y, decreases linearly to 0.Age distribution of active donors at DRK Blood Service West, by age at first donation
Risk of receiving transfusionsBimodal, with peaks for newborns and aged persons. Multiple transfusions possible.Data collected from 4,867 patients March 2003, University Hospital Essen, Germany
Transfusion-associated risk for deathIncreases according to a sigmoid function, ≈17% at birth to ≈48% in old age. For those with transfusion-associated risk for death, life expectancy is ≈2.5 years at birth and decreases to ≈0.5 y in old age.Follow-up of ≈3,000 transfusion recipients for ≈7.5 y in Newcastle, UK (4)
Alimentary infectionConstant over an initial period of 10 y.Arbitrary assumption
Incubation period†Gamma distributed with mean 16 y, SD 4 y. Sensitivity analysis with mean = 50 y and same coefficient of variation.Models fitted to the UK incidence of vCJD (5,6)
Donor exclusionEither 0 or 95% of those with transfusion history.Arbitrary assumption

*DRK, German Red Cross; SD, standard deviation; vCJD, variant Creutzfeldt-Jakob disease.
†Time between infection and death, i.e., duration of infection.

Main Article

  1. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.Lancet. 2004;363:41721. DOIPubMedGoogle Scholar
  2. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.Lancet. 2004;364:5279. DOIPubMedGoogle Scholar
  3. Castilla J, Saa P, Soto C. Detection of prions in blood.Nat Med. 2005;11:9825.PubMedGoogle Scholar
  4. Wallis JP, Wells AW, Matthews JN, Chapman CE. Long-term survival after blood transfusion: a population based study in the North of England.Transfusion. 2004;44:102532. DOIPubMedGoogle Scholar
  5. Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom.Science. 2001;294:17268. DOIPubMedGoogle Scholar
  6. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. Updated projections of future vCJD deaths in the UK.BMC Infect Dis. 2003;3:4. DOIPubMedGoogle Scholar
  7. Zerr I, Brandel JP, Masullo C, Wientjens D, de Silva R, Zeidler M, European surveillance on Creutzfeldt-Jakob disease: a case-control study for medical risk factors.J Clin Epidemiol. 2000;53:74754. DOIPubMedGoogle Scholar
  8. Bacchetti P. Unexamined assumptions in explorations of upper limit for cases of variant Creutzfeldt-Jakob disease.Lancet. 2001;357:34. DOIPubMedGoogle Scholar
  9. Bacchetti P. Age and variant Creutzfeldt-Jakob disease.Emerg Infect Dis. 2003;9:16112.PubMedGoogle Scholar
  10. Bacchetti P. Uncertainty due to model choice in variant Creutzfeldt-Jakob disease projections.Stat Med. 2005;24:8393. DOIPubMedGoogle Scholar
  11. Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies.Lancet. 2004;363:5161. DOIPubMedGoogle Scholar
  12. Clarke P, Ghani AC. Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility.J R Soc Interface. 2004;2:1931. DOIGoogle Scholar
  13. Velasco-Hernandez JX. A model for Chagas disease involving transmission by vectors and blood transfusion.Theor Popul Biol. 1994;46:131. DOIPubMedGoogle Scholar
  14. Roberts MG, Heesterbeek JA. A new method for estimating the effort required to control an infectious disease.Proc R Soc Lond B Biol Sci. 2003;270:135964. DOIGoogle Scholar
  15. Huang XC, Villasana M. An extension of the Kermack-McKendrick model for AIDS epidemic.Journal of the Franklin Institute–Engineering and Applied Mathematics.2005;342:34151. DOIGoogle Scholar
  16. Inaba H, Sekine H. A mathematical model for Chagas disease with infection-age-dependent infectivity.Math Biosci. 2004;190:3969. DOIPubMedGoogle Scholar
  17. Chadeau-Hyam M, Alperovitch A. Risk of variant Creutzfeldt-Jakob disease in France.Int J Epidemiol. 2005;34:4652. DOIPubMedGoogle Scholar
  18. German Federal Ministry of Health Working Group. Overall blood supply strategy with regard to variant Cruetzfeldt-Jakob disease (vCJD).Transfus Med Hemother. 2006;33(suppl 2):vii–39.

Main Article

Page created: June 28, 2010
Page updated: June 28, 2010
Page reviewed: June 28, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.